Position in REPL
as of Mar 31, 2026
· filed May 18, 2026
Position Value
$0
+$0 QoQ
Shares Held
0
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Derivatives in REPL
reported options exposure · as of Mar 31, 2026CallValue
$1,888,785
CallShares
246,900
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026Ally Bridge Group (NY) LLC holds $91,014,294 across 19 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PRAX |
Praxis Precision Medicines, Inc.
|
32,810 | $10,571,053 | |
| 2 | NERV |
Minerva Neurosciences, Inc.
|
1,655,500 | $9,974,387 | |
| 3 | SLNO |
Soleno Therapeutics Inc
|
200,000 | $6,696,000 | |
| 4 | OVID |
Ovid Therapeutics Inc.
|
2,818,459 | $6,256,978 | |
| 5 | TARS |
Tarsus Pharmaceuticals, Inc.
|
80,859 | $5,672,258 | |
| 6 | SLDB |
Solid Biosciences Inc.
|
766,974 | $5,522,212 | |
| 7 | PMN |
ProMIS Neurosciences Inc.
|
414,219 | $5,260,581 | |
| 8 | EWTX |
Edgewise Therapeutics, Inc.
|
161,000 | $5,071,500 |
All Filings in REPL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,888,785 | 246,900 | Call | Sole | 2026-05-18 | |
| 2025-12-31 | $11,664,000 | 1,200,000 | Call | Sole | 2026-02-17 | |
| 2025-09-30 | $15,084,000 | 3,600,000 | Call | Sole | 2025-11-14 | |
| 2025-06-30 | $4,909,681 | 528,491 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||